Naphthalene/quinoline amides and sulfonylureas as potent and selective antagonists of the EP4 receptor
✍ Scribed by Jason D. Burch; Julie Farand; John Colucci; Claudio Sturino; Yves Ducharme; Richard W. Friesen; Jean-François Lévesque; Sébastien Gagné; Mark Wrona; Alex G. Therien; Marie-Claude Mathieu; Danielle Denis; Erika Vigneault; Daigen Xu; Patsy Clark; Steve Rowland; Yongxin Han
- Publisher
- Elsevier Science
- Year
- 2011
- Tongue
- English
- Weight
- 755 KB
- Volume
- 21
- Category
- Article
- ISSN
- 0960-894X
No coin nor oath required. For personal study only.
✦ Synopsis
Two new series of EP(4) antagonists based on naphthalene/quinoline scaffolds have been identified as part of our on-going efforts to develop treatments for inflammatory pain. One series contains an acidic sulfonylurea pharmacophore, whereas the other is a neutral amide. Both series show subnanomolar intrinsic binding potency towards the EP(4) receptor, and excellent selectivity towards other prostanoid receptors. While the amide series generally displays poor pharmacokinetic parameters, the sulfonylureas exhibit greatly improved profile. MF-592, the optimal compound from the sulfonylurea series, has a desirable overall preclinical profile that suggests it is suitable for further development.
📜 SIMILAR VOLUMES
The identification of a novel dopamine receptor subtype, referred to as the D4 receptor, which binds the atypical antipsychotic drug clozapine with high potency, has led to the initiation of a drug discovery program that aims to find novel inhibitors of this receptor subtype. A selective screening s
## Abstract We previously reported a structure–activity study which identified Acid blue 129 (1‐amino‐4‐(2,4,6‐trimethylphenylamino)‐9,10‐dioxo‐9,10‐dihydroanthracene‐2‐sulfonic acid) as a highly selective antagonist at the P2Y‐receptor of the guinea pig taenia coli. In contrast to the less selecti
Novel Series of O-Substituted 8-Quinolines and 4-Benzothiazoles as Potent Antagonists of the Bradykinin B 2 Receptors. -The synthesized title series of 8-quinolines (VIII) and 4-benzothiazoles (IX) are investigated for the desired bradykinin B 2 receptor antagonistic activity. The 8-quinoline series